Embudo, Ziefforah A.

HRN: 21-63-93  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/17/2022
AMPICILLIN 250MG (VIAL)
08/17/2022
08/24/2022
IV
175mg
Q6h
Soft Tissue Abscess
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: